All In Biotech

Drug Trial Radar · NCT04662710

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)

Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 895 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

895

Actual

Start

Dec 30, 2020

Primary completion

Oct 29, 2024

Study completion Mar 30, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Eisai Inc.
First posted
Dec 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in participants with advanced/metastatic gastroesophageal cancer. The primary study hypotheses are that lenvatinib plus pembrolizumab plus chemotherapy is superior to chemotherapy alone for both overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), in participants with programmed cell death-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 and in all participants.

Conditions

  • Advanced/Metastatic Gastroesophageal Adenocarcinoma

Interventions

  • PembrolizumabBiological

    400 mg Q6W by IV infusion

  • LenvatinibBiological

    Administered PO QD, 8 mg induction/20 mg consolidation.

  • OxaliplatinDrug

    130 mg/m\^2 administered by IV infusion on Day 1 of Weeks 1 and 4 of each Q6W cycle as part of CAPOX chemotherapy, or 85 mg/m\^2 administered by IV infusion on Day 1 and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.

  • CapecitabineDrug

    1000 mg/m\^2 administered PO twice daily (BID) on Days 1-14, 22-35 of each Q6W cycle as part of CAPOX chemotherapy.

  • Leucovorin (or Levoleucovorin)Drug

    Administered by IV infusion at 400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) on Day 1, and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.

  • 5-FUDrug

    400 mg/m\^2 bolus IV infusion followed by 2400 mg/m\^2 continuous IV infusion administered on Day 1, and Week 1, 3, 5, of each Q2W cycle as part of mFOLFOX6 chemotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to ~21 days
  2. Part 1: Number of Participants With Adverse Events (AEs)Time frame: Up to ~44 months
  3. Part 1: Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to ~29 months
  4. Part 2: Overall Survival (OS) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1Time frame: Up to ~41 months
  5. Part 2: OS in All ParticipantsTime frame: Up to ~41 months
  6. Part 2: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 CPS ≥1Time frame: Up to ~29 months
  7. Part 2: PFS Per RECIST 1.1 as Assessed by BICR in All ParticipantsTime frame: Up to ~29 months

Locations

177 sites in 24 countries. Site status is shown where the registry gives one.

  • UCLA Hematology/Oncology - Santa Monica ( Site 0003)

    Los Angeles, California

  • Georgetown University Medical Center ( Site 0009)

    Washington D.C., District of Columbia

  • James Graham Brown Cancer Center ( Site 0017)

    Louisville, Kentucky

  • Johns Hopkins University ( Site 0052)

    Baltimore, Maryland

  • Dana Farber Cancer Center ( Site 0019)

    Boston, Massachusetts

  • UMASS Memorial Medical Center ( Site 0020)

    Worcester, Massachusetts

  • Henry Ford Health System ( Site 0023)

    Detroit, Michigan

  • Cancer and Hematology Centers of Western Michigan ( Site 0025)

    Grand Rapids, Michigan

  • Washington University School of Medicine ( Site 0027)

    St Louis, Missouri

  • Mount Sinai Hospital ( Site 0051)

    New York, New York

  • Memorial Sloan Kettering Cancer Center ( Site 0032)

    New York, New York

  • AHN West Penn Hospital-AHN Esophageal and Lung Institute ( Site 0058)

    Pittsburgh, Pennsylvania

  • Fundacion Favaloro ( Site 0201)

    Buenos Aires, Argentina

  • Hospital Aleman ( Site 0210)

    Buenos Aires, Argentina

  • Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0207)

    Buenos Aires, Argentina

  • CEMIC ( Site 0209)

    Buenos Aires, Argentina

  • Hospital Privado de Cordoba ( Site 0204)

    Córdoba, Argentina

  • IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 0202)

    Caba, Buenos Aires, Argentina

  • Instituto Medico Alexander Fleming ( Site 0208)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Nepean Hospital ( Site 2305)

    Kingswood, New South Wales, Australia

  • Wollongong Hospital ( Site 2307)

    Wollongong, New South Wales, Australia

  • Royal Brisbane and Women s Hospital ( Site 2304)

    Herston, Queensland, Australia

  • Hollywood Private Hospital-Medical Oncology ( Site 2308)

    Nedlands, Western Australia, Australia

  • CHU UCL Namur Site de Godinne ( Site 1005)

    Yvoir, Namur, Belgium

  • UZ Gent ( Site 1002)

    Ghent, Oost-Vlaanderen, Belgium

  • UZ Leuven ( Site 1004)

    Leuven, Vlaams-Brabant, Belgium

  • AZ Delta ( Site 1006)

    Roeselare, West-Vlaanderen, Belgium

  • Queen Elizabeth II Health Sciences Centre ( Site 0101)

    Halifax, Nova Scotia, Canada

  • Hamilton Health Sciences - Juravinski Site ( Site 0106)

    Hamilton, Ontario, Canada

  • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0103)

    Sherbrooke, Quebec, Canada

  • Centro Investigación del Cáncer James Lind ( Site 0414)

    Temuco, Araucania, Chile

  • IC La Serena Research ( Site 0410)

    La Serena, Coquimbo Region, Chile

  • Clinica Universidad Catolica del Maule ( Site 0411)

    Talca, Maule Region, Chile

  • Fundacion Arturo Lopez Perez FALP ( Site 0403)

    Santiago, Region M. de Santiago, Chile

  • Clínica San Carlos de Apoquindo Red Salud UC Christus ( Site 0407)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill ( Site 0404)

    Santiago, Region M. de Santiago, Chile

  • Anhui Provincial Hospital ( Site 2415)

    Hefei, Anhui, China

  • Cancer Hospital Chinese Academy of Medical Sciences ( Site 2403)

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital ( Site 2453)

    Beijing, Beijing Municipality, China

  • Fujian Provincial Cancer Hospital ( Site 2408)

    Fuzhou, Fujian, China

Showing 40 of 177 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.